Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: T1 high-grade (HG) non-muscle invasive bladder cancer (NMIBC) has a significant risk of recurrence and progression, and the European Association of Urology recommends a second transurethral resection of the bladder (ReTUR). Stage at ReTUR has been shown to be a reliable predictor of survival, therefore, we sought to assess clinical and pathological predictors associated with the persistence of T1 at ReTUR in our retrospective multicentric cohort.
Methods: This is a retrospective multicentric study of T1 HG patients at transurethral resection of the bladder (TURB) who underwent subsequent ReTUR. All histological samples were sub-classified according to Rete Oncologica Lombarda (ROL) T1 sub-staging system.
Results: One hundred and sixty-six patients were enrolled. Forty-four (26.5%) had T1 HG tumor at ReTUR while 93 (56%) had residual tumor of any stage. Lesion size was significantly greater in T1 HG patients at ReTUR, as well as the prevalence of multifocality. The multivariable logistic regression model showed lesion dimension and multifocality as predictors of T1 HG at ReTUR, after adjusting for significant covariables (CIS and detrusor muscle presence). ROL sub-staging system was not a significant predictor, but ROL2 prevalence was higher in the T1 HG at ReTUR group.
Conclusions: Lesion size and multifocality were independent predictors of T1 HG persistence at ReTUR, and patients at risk should be promptly identified and treated accordingly. Our results could help physicians make patient-tailored decisions by identifying those most likely to benefit from a second resection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350736 | PMC |
| http://dx.doi.org/10.1177/03915603231181619 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective Evaluation of the Effect of Vesical Imaging Reporting and Data System Scoring on the Identification of Candidates for Repeated Transurethral Resection.
J Laparoendosc Adv Surg Tech A
July 2025
Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
To determine the diagnostic accuracy of the Vesical Imaging Reporting and Data System (VI-RADS) scoring system in identifying candidates for second transurethral resection (reTUR-BT) and investigate the success of VI-RADS in detecting muscle-invasive bladder cancer (MIBC). Data from 186 patients who underwent primary TUR-BT for bladder cancer (BC) at our center between April 2022 and April 2023 were prospectively collected. Preoperative bladder multiparametric magnetic resonance imaging was performed for all patients to determine the VI-RADS score.
View Article and Find Full Text PDFUtility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review.
World J Urol
January 2025
Department of Urology, Paris Saint-Joseph Hospital, Paris, France.
Objective: This systematic review was conducted to synthesize current research on the role of repeated transurethral resection of the bladder (re-TURB) and the emerging use of magnetic resonance imaging (MRI) in discerning patient suitability for safely foregoing this procedure.
Evidence Acquisition: Employing a methodical literature search, we consulted several bibliographic databases including PubMed, Science Direct, Scopus, and Embase. The review process adhered strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines.
Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer.
World J Urol
August 2024
Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France.
Purpose: To assess prognostic significance of residual tumor at repeat transurethral resection (reTUR) in contemporary non-muscle-invasive bladder cancer (NMIBC) patients.
Methods: Patients were identified retrospectively from eight referral centers in France, Italy and Spain. The cohort included consecutive patients with high or very-high risk NMIBC who underwent reTUR and subsequent adjuvant BCG therapy.
Do we need a re-TUR after en bloc resection of T1 stage bladder cancer?
World J Urol
August 2024
Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse Oncopole, 1 Av Jean Poulhès, 31059, Toulouse, France.
Background: A second look trans-urethral resection of the bladder (re-TUR) is recommended after the diagnosis of T1 high grade (T1HG) bladder cancer. Few studies have evaluated the results of re-TUR after a first en bloc resection (EBR) and none of them have specifically reported the pathological results on the field of previous T1 disease.
Objective: To report the rate of upstaging and the rate of residual disease (RD) on the field of T1HG lesions resected with EBR.
Perioperative Patient Blood Management (excluding obstetrics): Guidelines from the French National Authority for Health.
Anaesth Crit Care Pain Med
October 2024
Département d'Anesthésie-Réanimation du CHU d'Angers, Faculté de Santé de l'Université d'Angers, Angers, France; Univ Angers, MITOVASC Inserm U1083 - CNRS 6015, Equipe CARME, Angers, France. Electronic address:
Article Synopsis
- The French National Authority for Health (HAS) has released new guidelines for patient blood management (PBM) during surgeries, focusing on three key areas: optimizing red blood cell count, minimizing blood loss, and managing anemia tolerance.
- Preoperative recommendations include identifying anemia and iron deficiency early, especially for surgeries with a higher risk of bleeding.
- Intraoperative strategies involve using tranexamic acid and certain surgical techniques to control bleeding, while postoperative guidance emphasizes reducing blood sampling and monitoring for anemia to determine if treatments like intravenous iron are needed.